钠依赖性葡萄糖协同转运蛋白 2 (SGLT 2) 市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按药物(Invokana、Jardiance、Farxiga/Forxiga 和 Suglat)和地理划分

市场快照

Sodium-Dependent Glucose Co-transporter 2 (SGLT2) Market Overview
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: Middle East and North Africa
Largest Market: North America
CAGR: >11 %
Sodium-Dependent Glucose Co-transporter 2 (SGLT2) Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

SGLT2 的市场在 2020 年价值 72 亿美元,预计到 2026 年复合年增长率将超过 11%。SGLT2 抑制剂类药物包括 Jardiance、Fraxiga、Inovokana 和 Suglat 等。由于 Jardiance 和 Farxiga 等药物的出现,预计对 SGLT2 的需求将大幅增长。不断增长的全球 2 型糖尿病人口促进了 SGLT2 药物的增长。全球 SGLT2 市场具有很高的增长潜力,因为糖尿病患者数量的增加以及他们对有助于降低高血糖水平的药物的需求,尽管他们正在服用二甲双胍和胰岛素等药物治疗方案。SGLT2 服务于这个特定目的。

报告范围

该报告包括对 SGLT2 抑制剂的完整研究,其中包括 Invokana、Jardiance、Farxiga 和 Suglat。该研究进一步分为区域和国家分析,涵盖 SGLT2 类中的所有药物。

By Drug
Sodium - Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2016 - 2026)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Geography
North America
United States (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Canada (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of North America (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Europe
France (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Germany (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Italy (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Spain (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
United Kingdom (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Russia (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Europe (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Latin America
Mexico (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Brazil (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Latin America (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Asia-Pacific
Japan (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Korea (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
China (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
India (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Australia (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Vietnam (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Malaysia (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Indonesia (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Philippines (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Thailand (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Asia-Pacific (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Middle-East and Africa
Saudi Arabia (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Iran (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Egypt (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Oman (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Africa (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Middle-East and Africa (Value and Volume 2016 - 2026)
By Drug (Invokana, Jardiance, Farxiga, Suglat)

Report scope can be customized per your requirements. Click here.

主要市场趋势

Jardiance 引领 SGLT2 市场。

Jardiance 于 2014 年在全球发布,是一种每日一次的口服药物,用于控制 2 型糖尿病患者的血糖水平。与 Invokana 相比,Jardince 的销量正在增加,患者更喜欢这种药物,因为与其他 SGLT2 药物相比,它通过帮助肾脏从血液中去除葡萄糖而具有较低的心血管疾病风险。Jardiance 占 2020 年全球 SGLT2 类药物销售额的 30% 以上。 

Sodium-Dependent Glucose Co-transporter 2 (SGLT2) Market Key Trends

65%的市场份额被北美占据。

北美占 2 型糖尿病人群的最高比例。不断增长的全球 2 型糖尿病人口促进了 SGLT2 药物的增长。该地区的价格相对较高。Jardiance 在美国 SGLT2 市场占有 50% 的市场份额。美国糖尿病协会护理标准推荐 empagliflozin(Jardiance 中的活性药物成分)作为唯一可降低成人 2 型糖尿病患者心血管死亡风险的糖尿病药物。每年约有 175 万美国公民被诊断出患有糖尿病。该国还拥有最高的肥胖人口,这是导致 2 型糖尿病的主要原因。全国2型糖尿病人群占所有糖尿病人群的95%。

Sodium-Dependent Glucose Co-transporter 2 (SGLT2) Market Growth by Region

竞争格局

钠依赖性葡萄糖协同转运蛋白 2 (SGLT 2) 市场高度整合,一些重要的制造商在全球市场占有一席之地。这些公司通过以新形式获得批准来加强其市场占有率。例如,在日本,Forxiga 在 2019 年也被批准用于患有 1 型糖尿病的成年人,无论 BMI 是多少。

RECENT DEVELOPMENTS

In November 2020, Forxiga is the first SGLT2 inhibitor approved in the EU for heart failure with reduced ejection fraction in adult patients with and without type-2 diabetes.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Sodium - Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2016 - 2026)

        1. 5.1.1.1 Invokana (Canagliflozin)

        2. 5.1.1.2 Jardiance (Empagliflozin)

        3. 5.1.1.3 Farxiga/Forxiga (Dapagliflozin)

        4. 5.1.1.4 Suglat (Ipragliflozin)

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume 2016 - 2026)

          1. 5.2.1.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        2. 5.2.1.2 Canada (Value and Volume 2016 - 2026)

          1. 5.2.1.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        3. 5.2.1.3 Rest of North America (Value and Volume 2016 - 2026)

          1. 5.2.1.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume 2016 - 2026)

          1. 5.2.2.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        2. 5.2.2.2 Germany (Value and Volume 2016 - 2026)

          1. 5.2.2.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        3. 5.2.2.3 Italy (Value and Volume 2016 - 2026)

          1. 5.2.2.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        4. 5.2.2.4 Spain (Value and Volume 2016 - 2026)

          1. 5.2.2.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        5. 5.2.2.5 United Kingdom (Value and Volume 2016 - 2026)

          1. 5.2.2.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        6. 5.2.2.6 Russia (Value and Volume 2016 - 2026)

          1. 5.2.2.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        7. 5.2.2.7 Rest of Europe (Value and Volume 2016 - 2026)

          1. 5.2.2.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume 2016 - 2026)

          1. 5.2.3.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        2. 5.2.3.2 Brazil (Value and Volume 2016 - 2026)

          1. 5.2.3.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        3. 5.2.3.3 Rest of Latin America (Value and Volume 2016 - 2026)

          1. 5.2.3.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume 2016 - 2026)

          1. 5.2.4.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        2. 5.2.4.2 South Korea (Value and Volume 2016 - 2026)

          1. 5.2.4.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        3. 5.2.4.3 China (Value and Volume 2016 - 2026)

          1. 5.2.4.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        4. 5.2.4.4 India (Value and Volume 2016 - 2026)

          1. 5.2.4.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        5. 5.2.4.5 Australia (Value and Volume 2016 - 2026)

          1. 5.2.4.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        6. 5.2.4.6 Vietnam (Value and Volume 2016 - 2026)

          1. 5.2.4.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        7. 5.2.4.7 Malaysia (Value and Volume 2016 - 2026)

          1. 5.2.4.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        8. 5.2.4.8 Indonesia (Value and Volume 2016 - 2026)

          1. 5.2.4.8.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        9. 5.2.4.9 Philippines (Value and Volume 2016 - 2026)

          1. 5.2.4.9.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        10. 5.2.4.10 Thailand (Value and Volume 2016 - 2026)

          1. 5.2.4.10.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume 2016 - 2026)

          1. 5.2.4.11.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume 2016 - 2026)

          1. 5.2.5.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        2. 5.2.5.2 Iran (Value and Volume 2016 - 2026)

          1. 5.2.5.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        3. 5.2.5.3 Egypt (Value and Volume 2016 - 2026)

          1. 5.2.5.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        4. 5.2.5.4 Oman (Value and Volume 2016 - 2026)

          1. 5.2.5.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        5. 5.2.5.5 South Africa (Value and Volume 2016 - 2026)

          1. 5.2.5.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume 2016 - 2026)

          1. 5.2.5.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2016 - 2026)

    2. 6.2 Type-2 Diabetes Population (2016 - 2026)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Eli Lilly

      2. 7.1.2 Janssen Pharmaceuticals

      3. 7.1.3 Bristol Myers Squibb

      4. 7.1.4 Boehringer Ingelheim

      5. 7.1.5 AstraZeneca

      6. 7.1.6 Astellas

    2. 7.2 MARKET SHARE ANALYSIS

      1. 7.2.1 Eli Lilly

      2. 7.2.2 Janssen Pharmaceuticals

      3. 7.2.3 Astellas

      4. 7.2.4 Boehringer Ingelheim

      5. 7.2.5 AstraZeneca

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market market is studied from 2016 - 2027.

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is growing at a CAGR of >11% over the next 5 years.

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is valued at 7 Billion USD in 2016.

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is valued at 12 Billion USD in 2027.

Middle East and North Africa is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Janssen Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, AstraZeneca Pharmaceuticals, Astellas are the major companies operating in Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!